Organisation paid for research Program year 2025 Source: CMS Open Payments

Southern Star Research Institute LLC

Neither a doctor nor a teaching hospital

Research payments

$1,834,688

340 payments

Through program year 2025, Southern Star Research Institute LLC is reported as receiving $1,834,688 in research payments, across 340 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$326,916	57
2024	Research	$151,581	32
2023	Research	$97,166	20
2022	Research	$180,834	16
2021	Research	$310,428	69
2020	Research	$755,362	142
2019	Research	$12,399	4

Breakdown

Who paid Research payments · program years 2019–2025

Eli Lilly and Company $662,745 58 payments
AbbVie, Inc. $517,689 128 payments
Takeda Pharmaceuticals U.S.A., Inc. $218,325 93 payments
Ironwood Pharmaceuticals, Inc $114,306 9 payments
Genentech, Inc. $114,096 16 payments
GlaxoSmithKline, LLC. $99,521 16 payments
Otsuka Pharmaceutical Development & Commercialization, Inc. $39,279 2 payments
Allergan Inc. $37,880 15 payments
F. Hoffmann-La Roche AG $30,846 3 payments

Studies the money was for Research payments · program years 2019–2025

UC P3: Double-Blind Treat Straight Through $144,942 19 payments
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease $139,424 5 payments
M14-675 $131,065 11 payments
A Phase 3, Multicenter, Open Label, Long Term Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Crohns Disease $128,141 10 payments
C3718-302 $114,306 9 payments
A Multicentre Randomized, Double-Blind, Placebo-Controlled Phase 2 Stu $99,521 16 payments
A Phase 3 Long-Term Safety Extension Study of Shp647 in Subjects With Moderate to Severe Ulcerative Colitis (Aida) $67,342 13 payments
M14-234 $65,525 10 payments
An Adaptive Phase 2, Randomized, Double Blind, Placebo Controlled Study of Ly3471851 (NKTR 358) in Patients With Moderately to Severely Active Ulcerative Colitis $65,428 4 payments
A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis Lucent 3 $48,882 8 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.